Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 4/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP7 | P09237 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980419 | 0.91 | KMT2A (0.55) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL6985012 | 0.83 | ALDH1A1 (0.43) | ADRB3ADRB2ADRB1MEN1KMT2A | |
| SCHEMBL6987545 | 0.77 | HRH3 (0.43) | ADRB3ADRB2ADRB1MEN1KMT2A | |
| SCHEMBL6985805 | 0.77 | ADRB3 (0.79) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL6985800 | 0.77 | ADRB3 (0.79) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL6984819 | 0.75 | ADRB3 (0.65) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL25758323 | 0.75 | L3MBTL1 (0.60) | L3MBTL1TSHRMAPK1RECQLMEN1 | |
| SCHEMBL6988523 | 0.74 | ADRB3 (0.67) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL6985766 | 0.73 | TSHR (0.61) | ADRB3ADRB2ADRB1L3MBTL1TSHR | |
| SCHEMBL7130017 | 0.72 | ADRB3 (0.65) | ADRB3ADRB2ADRB1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| CN-1455769-A | Cyclic amine sulfonamides as beta-3 adrenergic receptor agonists | WYETH LTD (US) | 2003-11-12 | — | — | CN | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.